ViewPoint is a preclinical-stage biotechnology company passionately committed to the discovery, development, and commercialization of treatments for diseases of protein misfolding, which is implicated in numerous common disorders of aging including cataracts and presbyopia. The Company was founded in 2014 based on technology developed in the lab of ViewPoint co-founder, Dr. Jason Gestwicki, at the University of Michigan in collaboration with the lab of Dr. Usha Andley at Washington University in St. Louis. ViewPoint has a world-class Scientific Advisory Board with decades of experience in the fields of protein misfolding, crystallin biology, cataract etiology and medicinal chemistry. Targeting α-crystallin, a genetically validated target that drives cataract pathology and presbyopia, ViewPoint is developing VP1-001, a small molecule that is active in preclinical models of age-related cataracts. VP1-001 is the first preclinical candidate from ViewPoint's discovery engine.